Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients

被引:8
|
作者
Oshima, Minako [1 ]
Deitiker, Philip [1 ]
Jankovic, Joseph [3 ]
Atassi, M. Zouhair [1 ,2 ]
机构
[1] Baylor Coll Med, Dept Biochem & Mol Biol, One Baylor Plaza, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA
关键词
Botulinum neurotoxin type A; Cervical dystonia; H-N domain; Synthetic peptides; T-cell epitopes; MHC control; RESPONDER MOUSE STRAINS; TETANUS TOXIN; LIGHT-CHAIN; IN-VITRO; ANTIBODIES; EPITOPES; RESIDUES-449-859; IMMUNOGENICITY; LYMPHOCYTES; PROFILES;
D O I
10.1016/j.jneuroim.2016.09.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have recently reported the submolecular T-cell recognition profile of the C-terminal half (H-C, residues 8551296) of the heavy (H) chain of botulinum neurotoxin type A (BoNT/A) with peripheral blood lymphocytes (PBL) from 25 BoNT-treated cervical dystonia (CD) patients. In the current study, we describe the mapping of the T-cell responses of the patients to the N-terminal half (H-N, residues 449-859) of the heavy chain by using 29 synthetic overlapping peptides encompassing the entire HN domain of BoNT/A. The profiles of the T-cell responses to the peptides varied among the patients. Samples from 14 patients treated solely with BoNT/A recognized 1-9 (average 3.7) peptides/sample at Z > 3.0 level. Three peptide regions representing residues 631-649, 659-677 and 743-761 were frequently recognized by 29-64% of the patients. In patients with positive anti-BoNT/A antibody responses the overall positive T-cell responses to the HN peptides were significantly increased compared to antibody-negative patients. Influence of treatment parameters on the T-cell recognition of the HN peptides was also observed. The results were compared with those of previously identified He region. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:36 / 46
页数:11
相关论文
共 34 条
  • [1] Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients
    Oshima, Minako
    Deitiker, Philip
    Jankovic, Joseph
    Aoki, K. Roger
    Atassi, M. Zouhair
    IMMUNOBIOLOGY, 2016, 221 (04) : 568 - 576
  • [2] The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule
    Oshima, Minako
    Deitiker, Philip
    Jankovic, Joseph
    Atassi, M. Zouhair
    IMMUNOLOGICAL INVESTIGATIONS, 2018, 47 (01) : 18 - 39
  • [3] Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment
    Atassi, M. Zouhair
    Dolimbek, Behzod Z.
    Jankovic, Joseph
    Steward, Lance E.
    Aoki, K. Roger
    MOLECULAR IMMUNOLOGY, 2008, 45 (15) : 3878 - 3888
  • [4] Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule
    Atassi, M. Zouhair
    Jankovic, Joseph
    Steward, Lance E.
    Aoki, K. Roger
    Dolimbek, Behzod Z.
    IMMUNOBIOLOGY, 2012, 217 (01) : 17 - 27
  • [5] Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A
    Dolimbek, Behzod Z.
    Aoki, K. Roger
    Steward, Lance E.
    Jankovic, Joseph
    Atassi, M. Zouhair
    MOLECULAR IMMUNOLOGY, 2007, 44 (05) : 1029 - 1041
  • [6] Immune recognition of botulinum neurotoxin B: Antibody-binding regions on the heavy chain of the toxin
    Dolimbek, Behzod Z.
    Steward, Lance E.
    Aoki, K. Roger
    Atassi, M. Zouhair
    MOLECULAR IMMUNOLOGY, 2008, 45 (04) : 910 - 924
  • [7] Autonomic cardiovascular function in patients with cervical dystonia treated with botulinum toxin type A
    Tiple, D.
    Strano, S.
    Colosimo, C.
    Fabbrini, G.
    Stivali, G.
    Calcagnini, G.
    Berardelli, A.
    MOVEMENT DISORDERS, 2006, 21 : S381 - S381
  • [8] Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies
    Atassi, M. Zouhair
    Dolimbek, Behzod Z.
    Jankovic, Joseph
    Steward, Lance E.
    Aoki, K. Roger
    IMMUNOBIOLOGY, 2011, 216 (07) : 782 - 792
  • [9] Neutralizing chimeric heavy-chain antibody targeting the L-HN domain of Clostridium botulinum neurotoxin type F
    Sun, Kaiyue
    Luo, Shudi
    Jiang, Yujia
    Guo, Jiazheng
    Wang, Xi
    Cheng, Kexuan
    Xu, Changyan
    Zhang, Yixiao
    Gao, Chen
    Lu, Jiansheng
    Du, Peng
    Yu, Yunzhou
    Wang, Rong
    Yang, Zhixin
    Zhou, Chunyang
    ARCHIVES OF TOXICOLOGY, 2024, 98 (12) : 4187 - 4195
  • [10] Efficacy and safety of NT 201, botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients
    Grafe, S.
    Comella, C.
    Jankovic, J.
    Truong, D.
    Hanschmann, A.
    MOVEMENT DISORDERS, 2009, 24 : S92 - S92